Our approach      Genetic vaccines      Adenovirus vector platform      Proprietary cell line      Good manufacturing      Papers      

Send by emailPrint this page
Our approach

At Okairos, we believe in pushing the boundaries of science in the search for breakthroughs. Our scientists are working on ground-breaking projects in our effort to create novel and important new vaccines.


Our efforts are focused on the discovery and development of novel genetic vaccines against a range of infectious diseases and cancer, using the company’s proprietary adenovirus vector technology.


Our adenovirus vector platform is generating a pipeline of T-cell vaccines against a range of infectious diseases. We have also developed a proprietary packaging cell line, Procell92, a crucial platform to support the development and commercialization of our vaccines.